Brief: Akari Therapeutics Regains Full Nasdaq Compliance
19/11/2024 13:20
Nov 19 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS REGAINS FULL NASDAQ COMPLIANCE
* AKARI THERAPEUTICS PLC - NASDAQ HEARING FOR AKARI
THERAPEUTICS
ON NOVEMBER 21 CANCELLED
Source text: ID:nGNX109G1z
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics